|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dynamic localization of hepatocellular transporters in health and disease显示文摘Vesicle-based traffi cking of hepatocellular transporters involves delivery of the newly-synthesized carriers from the rough endoplasmic reticulum to either the plasma membrane domain or to an endosomal,submembrane compartment,followed by exocytic targeting to the plasma membrane. Once delivered to the plasma membrane,the transporters usually undergo recycling between the plasma membrane and the endosomal compartment,which usually serves as a reservoir of pre-existing transporters available on demand. The balance between exocytic targeting and endocytic internalization from/to this recycling compartment is therefore a chief determinant of the overall capability of the liver epithelium to secrete bile and to detoxify endo and xenobiotics. Hence,it is a highly regulated process. Impaired regulation of this balance may lead to abnormal localization of these transporters,which results in bile secretory failure due to endocytic internalization of key transporters involved in bile formation. This occurs in several experimental models of hepatocellular cholestasis,and in most human cholestatic liver diseases. This review describes the molecular bases involved in the biology of the dynamic localization of hepatocellular transporters and its regulation,with a focus on the involvement of signaling pathways in this process. Their alterations in different experimental models of cholestasis and in human cholestatic liver disease are reviewed. In addition,the causes explaining the pathological condition (e.g. disorganization of actin or actin-transporter linkers) and the mediators involved (e.g. activation of cholestatic signaling transduction pathways) are also discussed. Finally,several experimental therapeutic approaches based upon the administration of compounds known to stimulate exocytic insertion of canalicular transporters (e.g. cAMP,tauroursodeoxycholate) are described. | Marcelo G Roma Fernando A Crocenzi Aldo D Mottino | 2008 | World Journal of Gastroenterology2008，14，44： | 2 |
| 2 | A Phase I, first- in-human, open label, dose escalation study of MGD007, a hu- manized gpA33 x CD3 dual-affinity re-targeting ( DART ) pro- tein in patients with relapsed/refractory metastatic colorectal car- cinoma显示文摘 | HURWITZ H CROCENZI T LOHR J | 2014 | J Immunother Cancer2014，2，3： | 1 |
| 3 | Impaired localisation and transport function of canalicular Bsep in taurolithocholate induced cholestasis in the rat显示文摘 | Crocenzi FA Mottino AD Sanchez Pozzi EJ | 2003 | Gut2003，52，8： | 1 |
| 4 | Silymarin as a new hepatoprotective a- gent in experimental cholestasis: new possibilities for an ancient medication 显示文摘 | Crocenzi F A Roma M G | 2006 | Curr Med Chem2006，13，9： | 1 |
| 5 | Phase I/U safety and antitumor activity of nivolumab in patients with advanced hepatoeellular carcinoma ( HCC ) : CA209-040 显示文摘 | El-Khoueiry AB Melero I Crocenzi TS | 2015 | J Clin Oncol2015，，： | 1 |
| 6 | Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets:Possible involvement ofcAMP显示文摘 | Crocenzi FA Basiglio CL Perez M | 2005 | Biochemical Pharmacology2005，69，： | 1 |
| 7 | Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication显示文摘 | Crocenzi FA Roma MG | 2006 | Curr Med Chem2006，13，： | 1 |
| 8 | Effect of silyma- rin on biliary bile salt secretion in the rat显示文摘 | Crocenzi FA Pellegrin JM Sanchez Pozzi-EJ | 2000 | Biochem Pharmacol2000，59，： | 1 |
| 9 | Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis显示文摘 | Robert C. G. Martin Charles R. Scoggins Marshall Schreeder William S. Rilling Christopher J. Laing Clifton M. Tatum Lawrence R. Kelly Ricardo D. Garcia‐Monaco Vivek R. Sharma Todd S. Crocenzi Steven M. Strasberg | 2015 | Cancer2015，，20： | 1 |
| 10 | Disruption of function and localization of tight junctional structures and Mrp2 in sustained estradiol-17beta-D-glucuronide-induced cholestasis显示文摘 | Mottino A D Hoffman T Crocenzi F A | 2007 | Am J Physiol Gastrointest Liver Physiol2007，293，1： | 1 |
| 11 | Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang显示文摘 | Ernstoff MS Crocenzi TS Seigne JD | 2007 | Clin Cancer Res2007，13，： | 1 |
| 12 | Developing a rationaltumor vaccine therapy for renal cell carcinoma : immune yin andyang显示文摘 | Emstoff M Crocenzi T Seigne J | 2007 | Clin Cancer Res2007，13，2： | 1 |
| 13 | Prevention of Mrp2 activity impairment in ethinylestradiol-induced cholestasis by ursodeoxycholate in the rat 显示文摘 | Crocenzi FA D'Andrea V Catania VA | 2005 | Drug Metab Dispos2005，33，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员